In April 2026, Wondfo Biotech Philippines Inc. celebrated its first anniversary, marking an important milestone in the company's global expansion strategy. Since its establishment in Taguig City, Metro Manila, the subsidiary has strengthened Wondfo's local operations and expanded its presence in the Southeast Asian IVD market through localized management, channel development, and regulatory progress.
Strengthening Wondfo's Presence in Southeast Asia
Following comprehensive market research in 2024, Wondfo officially established its wholly owned Philippine subsidiary on April 23rd, 2025. The opening ceremony was attended by Wondfo Chairman Jihua Wang, together with representatives from government agencies, healthcare institutions, and industry associations.
In September 2025, Wondfo Founder Wenmei Li visited the Philippines to review local operations and reinforce the company's commitment to accelerating its international growth strategy.
Building a Localized Team and Service Network
Guided by its customer-centric philosophy, Wondfo has built a localized professional team covering operations, sales, marketing, and technical support. With a deep understanding of local regulations and customer needs, the Philippine team has significantly improved response efficiency and customer engagement across the Philippine market.
The establishment of a localized service network has further strengthened Wondfo's operational capabilities and laid a solid foundation for sustainable growth in the country.
Expanding Channels and Advancing High-End Diagnostics
Over the past year, the Philippine subsidiary has achieved steady progress through a dual strategy targeting both public and private healthcare sectors.
Nationwide Channel Development
The subsidiary completed a comprehensive assessment of local distributors and healthcare resources while advancing product registration and regulatory compliance. By strengthening partnerships with local distributors, Wondfo has established an expanding nationwide distributor network and enhanced its access to healthcare institutions across the country.
Growing Adoption of Core Technologies
With more than 30 years of experience in in vitro diagnostics, Wondfo has developed diversified technology platforms and product portfolios covering cardiovascular and metabolic diseases, oncology, respiratory diseases, infectious diseases, women's health, and drugs of abuse testing.
In the Philippines, Wondfo's colloidal gold, immunofluorescence, and electrochemical platforms have already achieved broad market adoption. Following the establishment of the subsidiary, ACCRE CLIA platform continued to gain market traction, while the Fully-auto Chemiluminescence Quantitative Test System, SmarLumi™ FC-2100, gained increasing recognition in thrombosis and hypertension testing.
In addition, Wondfo successfully introduced its pathology diagnostics, digital slide scanning, and AI-assisted diagnostic solutions to leading private healthcare institutions in the Philippines, marking an important breakthrough in the high-end diagnostics segment.
Strengthening Academic Collaboration
The subsidiary has also established ongoing collaboration with national and regional medical experts and partnered with local professional associations to organize academic seminars and industry activities. Several key products have entered clinical evaluation stages, further strengthening Wondfo's professional brand presence in the market.
Driving Sustainable Growth
Looking ahead, Wondfo Philippines will continue to focus on four strategic priorities:
· Expanding the local core team and accelerating product registrations and certifications;
· Enhancing market penetration through existing distribution channels;
· Strengthening collaboration with key opinion leaders and leading healthcare institutions;
· Optimizing global supply chain capabilities and exploring innovative business models while maintaining strong operational risk control.
Moving forward, Wondfo will continue to strengthen its presence in the Philippines as a strategic hub for Southeast Asia, delivering innovative diagnostic technologies and high-quality services to support healthcare development across the region.
The first developed technology platform with various application scenarios, including infectious disease, fertility, DOA, etc.
50+ kinds of reagents and five high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.
Single-dose Chemiluminescense Immunoassay Platform
Wondfo optical blood coagulation analyzer is the first one in the world that can test PT, APTT, TT, FIB, and ACT simultaneously.
Our Blood Gas Analyzer BGA-102 can produce the result in 30s. Its advantages of portability, easy operation, durability, and high performance make it ideal for clinics, laboratories, and hospitals.
Ready-to-use lyophilized RT-PCR Reagent；
Wondfo PA-3600 IHC Staining System
The Wondfo Truth-H80E HPLC Hemoglobin Analyzer is a high-performance diagnostic device designed for rapid and precise measurement of glycosylated hemoglobin (HbA1c)—the gold standard for diabetes diagnosis.It support the standard mode and variant mode and provide the result within 60-90seconds.
Finecare™ Vitamin D, from complexity to simplicity
Building A World Free from Antibitoic Overuse
Advanced rapid diagnostic test with WHO prequalification for infectious disease
The Future Intelligent Medical Assistant to Healthcare
Fight against the pandemic through continuous innovation
